247 related articles for article (PubMed ID: 29519619)
21. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
22. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Abou Dalle I; Jabbour E; Short NJ; Ravandi F
Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
[TBL] [Abstract][Full Text] [Related]
24. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
Short NJ; Kantarjian H; Jabbour E; Ravandi F
Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
[TBL] [Abstract][Full Text] [Related]
25. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
26. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
[TBL] [Abstract][Full Text] [Related]
28. Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph'+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib.
Molica M; Mazzone C; Cordone I; Divona M; Niscola P; de Fabritiis P
Chemotherapy; 2021; 66(3):78-81. PubMed ID: 34102636
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
30. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
31. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
Haddad FG; Short NJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):213-217. PubMed ID: 36485089
[TBL] [Abstract][Full Text] [Related]
32. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Zhu Y; Zhu Y; Miao L; Jia T; Mao J; Xue L; Wang Y
Technol Cancer Res Treat; 2023; 22():15330338231165866. PubMed ID: 36959735
[TBL] [Abstract][Full Text] [Related]
34. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
Sasaki Y; Kantarjian HM; Short NJ; Wang F; Furudate K; Uryu H; Garris R; Jain N; Sasaki K; Ravandi F; Konopleva M; Garcia-Manero G; Little L; Gumbs C; Zhao L; Futreal PA; Takahashi K; Jabbour E
Leukemia; 2022 May; 36(5):1253-1260. PubMed ID: 35132195
[TBL] [Abstract][Full Text] [Related]
35. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
36. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Haddad FG; Kourie HR; Saleh K
Br J Haematol; 2023 Sep; 202(6):1084-1086. PubMed ID: 37525325
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Othman T; Moskoff BN; Ho G; Tenold ME; Azenkot T; Krackeler ML; Fisch SC; Potter LA; Kaesberg PR; Welborn JL; Wun T; Esteghamat NS; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
Leuk Res; 2022 Aug; 119():106885. PubMed ID: 35738024
[TBL] [Abstract][Full Text] [Related]
38. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
39. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
Malagola M; Papayannidis C; Baccarani M
Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]